{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T08:56:03Z","timestamp":1778576163153,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,12,22]],"date-time":"2010-12-22T00:00:00Z","timestamp":1292976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s10637-010-9618-9","type":"journal-article","created":{"date-parts":[[2010,12,21]],"date-time":"2010-12-21T01:50:52Z","timestamp":1292896252000},"page":"794-802","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate"],"prefix":"10.1007","volume":"30","author":[{"given":"Justine Yang","family":"Bruce","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Eickhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Pili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theodore","family":"Logan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Carducci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Arnott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Treston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Wilding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,22]]},"reference":[{"key":"9618_CR1","volume-title":"Cancer facts and figures 2010","author":"American Cancer Society","year":"2010","unstructured":"American Cancer Society (2010) Cancer facts and figures 2010. American Cancer Society, Atlanta"},{"key":"9618_CR2","unstructured":"Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators (1999). Lancet 353(9146):14\u201317. doi:S0140673698035442"},{"issue":"9","key":"9618_CR3","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","volume":"17","author":"S Pyrhonen","year":"1999","unstructured":"Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17(9):2859\u20132867","journal-title":"J Clin Oncol"},{"issue":"2","key":"9618_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. doi:356\/2\/115","journal-title":"N Engl J Med"},{"issue":"2","key":"9618_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125\u2013134. doi:356\/2\/125","journal-title":"N Engl J Med"},{"issue":"33","key":"9618_CR6","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422\u20135428. doi:JCO.2008.16.9847","journal-title":"J Clin Oncol"},{"key":"9618_CR7","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol doi:JCO.2009.23.9764"},{"issue":"4","key":"9618_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S1535-6108(03)00077-1","volume":"3","author":"NJ Mabjeesh","year":"2003","unstructured":"Mabjeesh NJ, Escuin D, LaVallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P (2003) 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4):363\u2013375. doi:S1535610803000771","journal-title":"Cancer Cell"},{"issue":"2","key":"9618_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1006\/bbrc.1996.1683","volume":"228","author":"H Attalla","year":"1996","unstructured":"Attalla H, Makela TP, Adlercreutz H, Andersson LC (1996) 2-Methoxyestradiol arrests cells in mitosis without depolymerizing tubulin. Biochem Biophys Res Commun 228(2):467\u2013473. doi:S0006-291X(96)91683-6","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"9618_CR10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1124\/mol.51.6.951","volume":"51","author":"TL Yue","year":"1997","unstructured":"Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ (1997) 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 51(6):951\u2013962","journal-title":"Mol Pharmacol"},{"issue":"2","key":"9618_CR11","first-page":"468","volume":"63","author":"TM LaVallee","year":"2003","unstructured":"LaVallee TM, Zhan XH, Johnson MS, Herbstritt CJ, Swartz G, Williams MS, Hembrough WA, Green SJ, Pribluda VS (2003) 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res 63(2):468\u2013475","journal-title":"Cancer Res"},{"issue":"6468","key":"9618_CR12","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/368237a0","volume":"368","author":"T Fotsis","year":"1994","unstructured":"Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L (1994) The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 368(6468):237\u2013239. doi:10.1038\/368237a0","journal-title":"Nature"},{"issue":"6","key":"9618_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.drup.2003.10.001","volume":"6","author":"SL Mooberry","year":"2003","unstructured":"Mooberry SL (2003) Mechanism of action of 2-methoxyestradiol: new developments. Drug Resist Updat 6(6):355\u2013361. doi:S1368764603001043","journal-title":"Drug Resist Updat"},{"issue":"2","key":"9618_CR14","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1592\/phco.23.2.165.32088","volume":"23","author":"NJ Lakhani","year":"2003","unstructured":"Lakhani NJ, Sarkar MA, Venitz J, Figg WD (2003) 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23(2):165\u2013172","journal-title":"Pharmacotherapy"},{"issue":"1","key":"9618_CR15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4161\/cbt.5.1.2349","volume":"5","author":"WL Dahut","year":"2006","unstructured":"Dahut WL, Lakhani NJ, Gulley JL, Arlen PM, Kohn EC, Kotz H, McNally D, Parr A, Nguyen D, Yang SX, Steinberg SM, Venitz J, Sparreboom A, Figg WD (2006) Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 5(1):22\u201327. doi:2349","journal-title":"Cancer Biol Ther"},{"issue":"1","key":"9618_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0169-409X(00)00120-4","volume":"47","author":"H Takeuchi","year":"2001","unstructured":"Takeuchi H, Yamamoto H, Kawashima Y (2001) Mucoadhesive nanoparticulate systems for peptide drug delivery. Adv Drug Deliv Rev 47(1):39\u201354. doi:S0169409X00001204","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"9618_CR17","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1158\/1078-0432.CCR-08-1599","volume":"15","author":"AJ Tevaarwerk","year":"2009","unstructured":"Tevaarwerk AJ, Holen KD, Alberti DB, Sidor C, Arnott J, Quon C, Wilding G, Liu G (2009) Phase I trial of 2-methoxyestradiol NanoCrystal dispersion in advanced solid malignancies. Clin Cancer Res 15(4):1460\u20131465. doi:15\/4\/1460","journal-title":"Clin Cancer Res"},{"issue":"13","key":"9618_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","volume":"35","author":"H Young","year":"1999","unstructured":"Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18 F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773\u20131782. doi:S0959804999002294","journal-title":"Eur J Cancer"},{"issue":"1","key":"9618_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ygyno.2009.05.042","volume":"115","author":"D Matei","year":"2009","unstructured":"Matei D, Schilder J, Sutton G, Perkins S, Breen T, Quon C, Sidor C (2009) Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol Oncol 115(1):90\u201396. doi:S0090-8258(09)00381-3","journal-title":"Gynecol Oncol"},{"issue":"18","key":"9618_CR20","doi-asserted-by":"publisher","first-page":"6625","DOI":"10.1158\/1078-0432.CCR-05-0440","volume":"11","author":"C Sweeney","year":"2005","unstructured":"Sweeney C, Liu G, Yiannoutsos C, Kolesar J, Horvath D, Staab MJ, Fife K, Armstrong V, Treston A, Sidor C, Wilding G (2005) A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 11(18):6625\u20136633. doi:11\/18\/6625","journal-title":"Clin Cancer Res"},{"issue":"6","key":"9618_CR21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.eururo.2008.07.051","volume":"54","author":"C Eichelberg","year":"2008","unstructured":"Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H, Heinzer H (2008) Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54(6):1373\u20131378. doi:S0302-2838(08)00899-3","journal-title":"Eur Urol"},{"issue":"1","key":"9618_CR22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cncr.24009","volume":"115","author":"AZ Dudek","year":"2009","unstructured":"Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C (2009) Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115(1):61\u201367. doi:10.1002\/cncr.24009","journal-title":"Cancer"},{"issue":"1","key":"9618_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.juro.2007.08.127","volume":"179","author":"I Tamaskar","year":"2008","unstructured":"Tamaskar I, Garcia JA, Elson P, Wood L, Mekhail T, Dreicer R, Rini BI, Bukowski RM (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179(1):81\u201386. doi:S0022-5347(07)02293-8, discussion 86","journal-title":"J Urol"},{"key":"9618_CR24","unstructured":"Rini BI, Hutson TE, Elson P, Heng DY, Knox JJ, Michaelson D, Choueiri TK, Escudier B (2010) Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma. ASCO GU Cancer Symposium (Meeting article) 145 (abstr 319)"},{"key":"9618_CR25","doi-asserted-by":"publisher","unstructured":"Zhou Q, Gustafson D, Nallapareddy S, Diab S, Leong S, Lewis K, Gore L, Messersmith WA, Treston AM, Eckhardt SG, Sidor C, Camidge DR A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Invest New Drugs. doi:10.1007\/s10637-009-9383-9","DOI":"10.1007\/s10637-009-9383-9"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-010-9618-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9618-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-010-9618-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:21:46Z","timestamp":1678558906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-010-9618-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,22]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["9618"],"URL":"https:\/\/doi.org\/10.1007\/s10637-010-9618-9","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,22]]},"assertion":[{"value":"22 October 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}